Product
PLD Chemotherapy
1 clinical trial
1 indication
Indication
Triple Negative Breast CancerClinical trial
Phase 1 Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Ligand in Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-20